

<h3>Bibliografía</h3>

    <ol>
        <li>Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med 2001;344(23):1773-9.</li>
        <li>Swystun LL, James PD. Genetic diagnosis in hemophilia and von Willebrand disease. Blood Rev 2017;31(1):47-56.</li>
        <li>Hoyer LW. Hemophilia A. N Engl J Med 1994;330(1):38-47.</li>
        <li>Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, et al. Characterization of the human factor VIII gene. Nature 1984;312(5992):326-30.</li>
        <li>Vehar GA, Keyt B, Eaton D, Rodríguez H, O’Brien DP, Rotblat F, et al. Structure of human factor VIII. Nature 1984;312(5992):337-42.</li>
        <li>EAHAD. Factor VIII Gene (F8). Variant Database. Available from: <a href="http://www.factorviii-db.org/" target="_blank">http://www.factorviii-db.org/</a></li>
        <li>Rossetti LC, Radic CP, Abelleyro MM, Larripa IB, de Brasi CD. Eighteen years of molecular genotyping the hemophilia inversion hotspot: from southern blot to inverse shifting-PCR. Int J Mol Sci 2011;12(10):7271-85.</li>
        <li>Bagnall RD, Waseem N, Green PM, Giannelli F. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood 2002;99(1):168-74.</li>
        <li>Dolan G, Benson G, Duffy A, Hermans C, Jiménez-Yuste V, Lambert T, et al. Haemophilia B: Where are we now and what does the future hold? Blood Rev 2018;32(1):52-60.</li>
        <li>Rodríguez-Merchan EC, Jiménez-Yuste V, Aznar JA, Hedner U, Knobe K, Lee CA, et al. Joint protection in haemophilia. Haemophilia 2011;17(Suppl 2):1-23.</li>
        <li>Peyvandi F, Klamroth R, Carcao M, Federici AB, G DIM, Jiménez-Yuste V, et al. Management of bleeding disorders in adults. Haemophilia 2012;18(Suppl 2):24-36.</li>
        <li>Berntorp E, Astermark J, Bjorkman S, Blanchette VS, Fischer K, Giangrande PL, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003;9(Suppl 1):1-4.</li>
        <li>Manco-Johnson MJ, Abshire TC, Valentino LA, Shapiro AD, Riske B, Hacker MR, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357(6):535-44.</li>
        <li>Srivastava A. Dose and response in haemophilia-optimization of factor replacement therapy. Br J Haematol. 2004;127(1):12-25.</li>
        <li>Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemophilia 1995;1(Suppl 1):8-13.</li>
        <li>Mancuso ME, Santagostino E. Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates. J Clin Med 2017;6(4). PII: E39. DOI: 10.3390/jcm6040039.</li>
        <li>Leissinger CA. Inhibitor development in patients with hemophilia: an overview. Semin Hematol 2006;43(2 Suppl 4):S1-2.</li>
        <li>Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003;9(4):418-35.</li>
        <li>Goudemand J. Hemophilia. Treatment of patients with inhibitors: cost issues. Haemophilia 1999;5(6):397-401.</li>
        <li>Kempton CL, White GC, 2nd. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009;113(1):11-7.</li>
        <li>Oldenburg J, Schroder J, Brackmann HH, Muller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004;41(1 Suppl 1):82-8.</li>
        <li>Berntorp E, Collins P, D’Oiron R, Ewing N, Gringeri A, Negrier C, et al. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition. Haemophilia 2011;17(1):e202-10.</li>
    </ol>